Next Article in Journal
5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs
Previous Article in Journal
DLEC1 Expression Is Modulated by Epigenetic Modifications in Hepatocelluar Carcinoma Cells: Role of HBx Genotypes
Previous Article in Special Issue
A Quest for Initiating Cells of Head and Neck Cancer and Their Treatment
Article Menu

Export Article

Open AccessReview
Cancers 2010, 2(3), 1705-1716;

Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer

Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Hollings Cancer Center, Medical University of South Carolina, Charleston SC 29425 USA
Author to whom correspondence should be addressed.
Received: 28 August 2010 / Accepted: 14 September 2010 / Published: 16 September 2010
(This article belongs to the Special Issue Biomarkers: Oncology Studies)
Full-Text   |   PDF [269 KB, uploaded 16 September 2010]   |  


Aberrant crypt foci (ACF) are one of the earliest histopathological manifestations of colon cancer. In this review, we critically present the molecular, cellular, histopathological, and chemopreventive evidence that ACF are relevant biomarkers for colon cancer. The laboratory and clinical evidence are highly suggestive that ACF are in the pathway leading to colon cancer, but not all ACF will do so. The possible fate and outcome of ACF in the progression toward colon cancer may be dependent on a number of features that define their predictive power for the prevention or progression of cancer. View Full-Text
Keywords: aberrant crypt foci; biomarker; colon cancer; chemoprevention aberrant crypt foci; biomarker; colon cancer; chemoprevention

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Wargovich, M.J.; Brown, V.R.; Morris, J. Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer. Cancers 2010, 2, 1705-1716.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top